Cargando…
Infusion-related events during natalizumab: No need for post-infusion monitoring
This retrospective cohort study assessed the timing of infusion-related adverse events (IAEs) during natalizumab (NTZ) administration in well-documented relapsing-remitting multiple sclerosis (RRMS) patients who had received NTZ infusions in our centre between 2006 and 2018. In 225 RRMS patients (14...
Autores principales: | Loonstra, Floor C, van Rossum, Johannis A, van Kempen, Zoé LE, Rispens, Theo, Uitdehaag, Bernard MJ, Killestein, Joep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575291/ https://www.ncbi.nlm.nih.gov/pubmed/31237826 http://dx.doi.org/10.1177/1352458519860415 |
Ejemplares similares
-
Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017) -
Fingerprick blood samples to measure serum natalizumab
concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022) -
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021) -
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017) -
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)